Neuroimaging and CSF Biomarker Program

ALZHEIMER'S DRUG DISCOVERY FOUNDATION (ADDF)

Objecte

Topic: Alzheimer.

Destination: The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use. Specifically, this RFP focuses on:

  • Developing novel PET ligands for clinical trials
  • Supporting novel CSF biomarkers
  • Validating innovative MRI approaches in larger cohorts
  • Developing novel measures of functional activity such as EEG

Budget: Up to 600,000 $ based on stage and scope of research.

Duration: 1 year with potential for follow-on funding.

Are you interested in this call?

Estàs interessat?

Omple el següent formulari per rebre més informació: